Kurs & Likviditet
|2022-04-29||Ordinarie utdelning VIRO 0.00 DKK|
|2021-04-28||Ordinarie utdelning VIRO 0.00 DKK|
|2020-06-19||Ordinarie utdelning VIRO 0.00 DKK|
|2019-04-26||Ordinarie utdelning VIRO 0.00 DKK|
|Lista||First North Denmark|
6.12.2021 15:30:01 CET | ViroGates | Company Announcement
COMPANY ANNOUNCEMENT - No. 23-2021 – Inside information - 6 December 2021
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces a development, supply and collaboration agreement with Italy-based DIESSE Diagnostica Senese S.p.A. for adaption of suPARnostic® ELISA on DIESSE’s Chorus Trio platform.
Italy-based DIESSE has developed an immunoassay analyzer system based on disposable diagnostic devices called Chorus Trio. The system has over 150 available tests in more than 3,000 clinical units ranging from hospitals to larger health clinics in approximately 100 countries.
ViroGates and DIESSE have already conducted feasibility studies showing that the suPARnostic® ELISA product can be adapted to run on the Chorus Trio platform and deliver results in less than one hour. The Chorus platform is particularly suited for batch collection and analysis of suPAR on a small to medium amount of samples. It will be important in handling COVID-19 samples in many hospitals that do not have access or capacity to run high-throughput systems like the suPARnostic® TurbiLatex.
The feasibility studies will be followed by required CE-IVD testing. The final product is expected to be available in the market in Q1, 2022.
The clinical benefit will primarily be faster COVID-19 triaging processes with more early discharge decisions. In addition, the clinical benefit could be more effective triage for therapeutic intervention of patients that risk developing a more severe condition after a COVID-19 infection, as demonstrated by the SAVE-MORE trial.
CEO Jakob Knudsen says in a comment: ”We are excited to work with DIESSE to bring suPARnostic® to a broader audience of clinicians. DIESSE has an extensive commercial reach and proprietary platforms to serve clinics. We believe that upon the finalization of the CE-IVD process, we will reach target hospitals and other clinical units efficiently. This product will complement our existing portfolio in segments that would otherwise be difficult for us to reach.”
Massimiliano Boggetti, CEO of DIESSE, says: “Consistent with our commitment to support the fight against SARSCoV-2 virus and after more than 13 kits developed since the pandemic started under the brand DIESSE4COVID19, we offer now our large Installed base to the suPAR testing. We are very proud that ViroGates has chosen Chorus as the monotest platform of choice to extend the suPARnostic® testing around the world. ”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: email@example.com
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: firstname.lastname@example.org
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 750 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.
DIESSE is an Italian company with an integrated and entirely inhouse production of in vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems primarily in the field of immunodiagnostics and automatic measurement of erythrocyte sedimentation rate (ESR). The company has a global presence in over 100 countries, three production sites and a research centre where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, making Diesse synonymous with “Diagnostics Evolution”. Link to the Chorus Trio system https://www.diesse.it/en/products/chorustrio/
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, email@example.com